STOCK TITAN

Theravance Bioph - TBPH STOCK NEWS

Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.

Overview of Theravance Biopharma Inc

Theravance Biopharma Inc (NASDAQ: TBPH) is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. With a solid foundation built on internally discovered product candidates and strategic partnerships, the company has positioned itself as a key player in addressing critical unmet needs in the treatment of respiratory and neurological disorders. Utilizing advanced research methodologies and precision medicine approaches, Theravance Biopharma aims to maximize therapeutic efficacy while minimizing systemic side effects.

Core Business and Product Portfolio

At its core, Theravance Biopharma invests heavily in the development of small-molecule drugs designed for organ-selective targeting. This strategy is exemplified by its FDA-approved product, YUPELRI (revefenacin) inhalation solution, which is the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company’s approach in leveraging organ-selectivity not only underpins its ability to deliver sustained improvements in pulmonary function but also highlights its commitment to addressing patient-specific needs through enhanced treatment outcomes.

Innovative Research and Development Strategy

Theravance Biopharma distinguishes itself through a robust, internally focused research and development platform. The company pioneers a new generation of small molecule drugs by applying its expertise in organ-selectivity to target diseases biologically. This approach is particularly significant in the field of inflammation and immunology where therapeutic indices can be expanded, thereby maximizing benefits while reducing systemic exposure. In addition to YUPELRI, the company is advancing a pipeline of promising product candidates, including ampreloxetine—an investigational agent developed as a once-daily norepinephrine reuptake inhibitor intended to manage symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA).

Strategic Collaborations and Market Position

Theravance Biopharma’s operational strategy is enhanced by strategic collaborations with other pharmaceutical companies. These partnerships not only complement the company’s internal discovery efforts but also provide additional avenues to accelerate clinical development, expand market reach, and optimize commercialization strategies. The unique collaboration dynamics, such as those with global commercial partners, reinforce the company’s capacity to navigate the competitive landscape and address market challenges effectively, making it a significant entity within the biopharmaceutical sector.

Expertise and Industry Credibility

The company’s demonstrated ability to innovate in the field of organ-selective medicine reflects deep scientific expertise and rigorous research methodologies. By combining academic research, clinical insights, and regulatory know-how, Theravance Biopharma has established a reputation for both innovation and reliability in its therapeutic niche. The consistent focus on delivering measurable clinical benefits, backed by peer-reviewed studies and rigorous clinical trial designs, further enhances its authority within the competitive landscape of respiratory and neurological therapeutics.

Comprehensive Business Model and Value Proposition

Theravance Biopharma’s business model revolves around the development and commercialization of a targeted portfolio that maximizes therapeutic efficacy while addressing market needs through innovative medicine. The company’s dual focus on an approved, commercially successful product and a robust pipeline of candidate drugs positions it well within its market segment. Although complex market dynamics and regulatory challenges exist, its disciplined approach to research and clinical development reinforces its stand as a scientifically driven enterprise dedicated to creating medicines that make a difference.

Investor and Market Insights

For investors and market researchers, Theravance Biopharma represents a blend of innovative research coupled with a commercially validated product. Its trajectory showcases an interplay between internally driven discovery and collaborative strength, which is reflected in its ever-expanding clinical developments and its focused approach toward addressing diseases with significant unmet patient needs. The company continually refines its research and development strategies, ensuring that its product portfolio remains both relevant and robust in an evolving therapeutic landscape.

Rhea-AI Summary

Theravance Biopharma, listed on NASDAQ as TBPH, will participate in the Bank of America 2021 Healthcare Conference on May 13 at 2:45 p.m. ET. CEO Rick E Winningham will present during the event, which can be accessed via a webcast on the company's website. The presentation will focus on the company's mission to develop organ-selective medicines aimed at improving patient outcomes in serious illnesses, particularly in inflammation and immunology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (TBPH) reported Q1 2021 total revenue of $14.3 million, a decrease of $5.6 million YOY, attributed mainly to collaboration revenue from Viatris. While YUPELRI's market share grew to 19%, overall net sales faced a slight decline. R&D expenses increased to $67.6 million, leading to an operating loss of $83.9 million. The company anticipates full-year R&D expenses between $195 million and $225 million. Notable upcoming clinical milestones include results for nezulcitinib and izencitinib trials expected in Q2 and Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines and aims to improve patient lives. Its notable product includes YUPELRI® for COPD. This update will provide critical insights into financial performance and business developments crucial for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences earnings
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in a pre-recorded Fireside Chat at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Interested investors can access the webcast through the 'Investors' section of Theravance's website, specifically under 'Events and Presentations.' A replay of the event will be available for at least 30 days. Theravance Biopharma focuses on developing organ-selective medicines, particularly in the areas of inflammation and immunology, aiming to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (TBPH) announced its financial results for Q4 and full year 2020, highlighting 159% year-over-year sales growth for YUPELRI, now capturing 18.6% of the nebulized COPD market. Despite this growth, total revenue for Q4 decreased by $10.8 million to $18.7 million, with a full year revenue of $71.9 million. Operating loss increased to $76.5 million in Q4. The company is optimistic about ongoing clinical trials, particularly for TD-0903 in COVID-19 patients, and expects significant milestones in 2021, including data releases for ongoing studies. Cash reserves stood at $292.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced its participation in key investor events. Management will engage in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 p.m. ET. Additionally, Richard A. Graham will join the GI/Microbiome Panel at the Cowen 41st Annual Cowen Conference on March 2 at 11:10 a.m. ET. Interested investors can access the webcast via the "Investors" section on Theravance's website, where replays will be available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after market close. A conference call and webcast are scheduled for 5:00 p.m. ET. The company focuses on organ-selective medicines, targeting inflammation and immunology. Notably, it has developed YUPELRI®, an inhalation solution for COPD. The announcement may impact investors keen on financial performance metrics and future growth prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
conferences earnings
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. ET. The presentation will focus on the company's commitment to developing organ-selective medicines aimed at treating serious illnesses, particularly in inflammation and immunology. Investors can access the webcast on the company's website and the replay will be available for 30 days. Theravance's research includes the approved YUPELRI® inhalation solution for COPD, showcasing its focus on patient-centered drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will webcast its presentation at the 3rd Annual Evercore ISI HEALTHCONx Conference on December 1, 2020, at 2:40 p.m. ET. The webcast can be accessed via the Investors section of their website www.theravance.com. Replay will be available for 30 days. The company specializes in organ-selective medicines, focusing on inflammation and immunology, with an aim to improve patient lives. Their notable product includes YUPELRI®, an FDA-approved treatment for chronic obstructive pulmonary disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) reported Q3 2020 total revenue of $18.3 million, driven by a significant rise in YUPELRI's sales, which contributed approximately $13.0 million to the revenue. However, the company reported an operating loss of $76.6 million due to increased R&D and SG&A expenses, totaling $67.4 million and $27.5 million respectively. Cash reserves stood at $358.3 million. Despite market challenges from COVID-19, YUPELRI gained market share and brand profitability. The company also anticipates key clinical trial results in Q3 2021 for its pipeline products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.81%
Tags

FAQ

What is the current stock price of Theravance Bioph (TBPH)?

The current stock price of Theravance Bioph (TBPH) is $8.44 as of April 4, 2025.

What is the market cap of Theravance Bioph (TBPH)?

The market cap of Theravance Bioph (TBPH) is approximately 421.7M.

What is Theravance Biopharma's core business?

Theravance Biopharma focuses on the discovery, development, and commercialization of organ-selective medicines. Its strategy centers on creating small-molecule drugs that maximize efficacy and minimize systemic side effects.

What key products does the company offer?

The company’s flagship product is YUPELRI, an FDA-approved, once-daily nebulized long-acting muscarinic antagonist for COPD maintenance. Additionally, it is advancing ampreloxetine in its pipeline for neurological indications.

How does Theravance Biopharma generate revenue?

Revenue is primarily generated through the commercialization of its approved product, YUPELRI, and through strategic collaborations that bolster its clinical development and market reach.

What distinguishes its research and development strategy?

Theravance Biopharma applies organ-selective targeting to enhance the therapeutic index of its medicines. Its robust internal discovery engine, combined with strategic partnerships, underpins its innovative R&D approach.

How does the company maintain its industry credibility?

The company leverages decades of research, peer-reviewed clinical studies, and rigorous trial designs, all of which reinforce its scientific expertise and build trust within the medical and investor communities.

What are the potential challenges it faces?

Challenges include navigating regulatory requirements, managing clinical trial complexities, and addressing competitive pressures. However, its strategic collaborations and focused R&D provide a strong foundation to meet these challenges.
Theravance Bioph

Nasdaq:TBPH

TBPH Rankings

TBPH Stock Data

421.74M
46.39M
6.22%
93.64%
7.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
GEORGE TOWN, GRAND CAYMAN